Abstract Body

Background

To accelerate development of pediatric antiretroviral formulations for children, the WHO-led Paediatric Antiretroviral Drug Optimization group regularly reviews priorities for drug development. High on this priority list is a dispersible fixed dose combination of dolutegravir (DTG), emtricitabine (FTC) and tenofovir alafenamide fumarate (TAF) for treatment of ART naïve and experienced children living with HIV. The optimal dose ratio for this novel DTG/FTC/TAF pediatric tablet is 5/15/1.88 mg and is based on pharmacokinetic (PK) modelling. The aim of the UNIVERSAL1 study (#NCT05993767) was to confirm if the proposed dose ratio achieves safe and effective exposures within each of the WHO weight-bands (WB). 

Methods

Eligible children with HIV, aged 28 days to ≤10 years and weighing ≥3-<25kg, switched therapy to a once-daily regimen of DTG and FTC/TAF administered as two separate formulations. Children received WB-based doses shown in the table. Children 3-<20 kg received dispersible tablets and those 20-<25 kg received adult film-coated tablets. We aimed for ≥8 participants evaluable for PK per WB. Seven blood samples were drawn at steady-state in a fed state pre-dose (t=0), and at 0.5, 1, 2, 4, 6 and 24h post dosing for noncompartmental PK analysis.

Results

51 children were included. Median (range) age and weight were 3.2 years (0.2-8.7) and 12.1 kg (4.4-22.6), respectively, and 39 (76%) had HIV RNA <400 copies/mL at screening. The PK parameters for DTG, FTC, TAF and tenofovir (TFV) are shown in the table. DTG PK parameters were overall higher than observed in CHAPAS-4, the paediatric reference study, yet AUC0-24h values were comparable to PK data of DTG once and twice daily in adults. No children had DTG Ctrough below the EC90 of 0.32 mg/L. FTC PK parameters were comparable to adult data. Despite variability in PK parameters of TAF and TFV across WBs, only one child had a TAF AUClast below the lower limit of the exposure range associated with virological efficacy of 30.3 h*ng/mL and none had a TFV AUC0-24h above the toxicity target of 2590 ng*h/mL. 

Conclusions

PK results of UNIVERSAL1 demonstrate that administration of DTG and FTC/TAF once-daily dispersible tablets in a dose ratio of 5/15/1.88 mg in children weighing 3-<20 kg and 50/200/25 mg film-coated tablets to those weighing 20-<25 kg results in DTG exposure comparable to that of DTG (once and twice daily) and FTC in adults. TAF and TFV exposures varied over the WBs but were within limits considered to be safe and effective. 

Table or Figure